United Therapeutics Corporation
United Therapeutics Corporation (UTHR) Stock Overview
Explore United Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
21.5B
P/E Ratio
16.22
EPS (TTM)
$26.37
ROE
0.19%
UTHR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of United Therapeutics Corporation (UTHR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 46.10, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $451.16.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 16.22 and a market capitalization of 21.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.